Video

Dr. Zhang on adaptive phase 3 trial of nivolumab, ipilimumab, and cabozantinib in kidney cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE study (NCT03793166) exploring immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) followed by nivolumab or nivolumab with cabozantinib (Cabometyx) for patients with intermediate/poor-risk metastatic clear cell renal cell carcinoma

      Zhang, who is an associate professor at UT Southwestern Medical Center, was interviewed during the 2021 Kidney cancer research summit in Philadelphia, Pennsylvania.

      Related Videos
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Martin Sanda, MD, considers potential future advancements in urology
      Martin Sanda, MD, considers potential future advancements in urology
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Chad Tang, MD: Considerations for SBRT in metastatic RCC
      Chad Tang, MD: Considerations for SBRT in metastatic RCC
      Related Content
      3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      May 19th 2025

      Patient selection for cytoreductive nephrectomy in 2025

      Daniel D. Shapiro, MD, FACS E. Jason Abel, MD, FACS
      "Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
      Destigmatizing Urology: Dr. Pettaway discusses penile cancer
      March 29th 2022

      Destigmatizing Urology: Dr. Pettaway discusses penile cancer

      Urology Times staff
      “When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.
      Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
      May 14th 2025

      Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer

      Hannah Clarke
      ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
      Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
      March 31st 2021

      Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists

      Urology Times staff
      “Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
      April 3rd 2025

      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

      Mehmet Asim Bilen, MD Hannah Clarke
      "The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
      Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
      April 2nd 2025

      The importance of federal funding in cancer research: A call to action

      Michael S. Cookson, MD, MMHC
      "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
      © 2025 MJH Life Sciences

      All rights reserved.